{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:19:36Z","timestamp":1786997976154,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"2-4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.vetimm.2009.05.007","type":"journal-article","created":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T05:23:08Z","timestamp":1242710588000},"page":"243-250","source":"Crossref","is-referenced-by-count":21,"title":["Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation"],"prefix":"10.1016","volume":"132","author":[{"given":"Emir","family":"Hadzijusufovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gruze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuddow","family":"Thaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Yuzbasiyan-Gurkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vetimm.2009.05.007_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1309\/M9FQMQGF66167N2X","article-title":"Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders","volume":"125","author":"Agis","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/00480169.2000.36176","article-title":"Splenic mast cell tumour and mastocytaemia in a cat: case study and literature review","volume":"48","author":"Allan","year":"2000","journal-title":"N. Z. Vet. J."},{"key":"10.1016\/j.vetimm.2009.05.007_bib5","first-page":"406","article-title":"Tumours and tumour-like lesions","volume":"vol. 1","author":"Carpenter","year":"1987"},{"key":"10.1016\/j.vetimm.2009.05.007_bib6","first-page":"160","article-title":"Long-term survival of two cats with mastocytosis","volume":"172","author":"Confer","year":"1978","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.vetimm.2009.05.007_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2460\/ajvr.2002.63.1129","article-title":"Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats","volume":"63","author":"Dank","year":"2002","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.vetimm.2009.05.007_bib8","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2460\/ajvr.2002.63.1718","article-title":"Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs","volume":"63","author":"Downing","year":"2002","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.vetimm.2009.05.007_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.vetimm.2009.05.007_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vetimm.2009.05.007_bib11","first-page":"965","article-title":"The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others","volume":"142","author":"Galli","year":"1993","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.vetimm.2009.05.007_bib14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.exphem.2007.06.005","article-title":"Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells","volume":"35","author":"Gleixner","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","article-title":"KIT mutations in mastocytosis and their potential as therapeutic targets","volume":"26","author":"Gotlib","year":"2006","journal-title":"Immunol. Allergy Clin. North. Am."},{"key":"10.1016\/j.vetimm.2009.05.007_bib16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816 V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1748-5827.1979.tb06691.x","article-title":"Systemic mastocytosis in a cat: remission after splenectomy","volume":"20","author":"Guerre","year":"1979","journal-title":"J. Small Anim. Pract."},{"key":"10.1016\/j.vetimm.2009.05.007_bib18","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.vetimm.2009.05.007_bib19","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.vetimm.2006.07.004","article-title":"Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate","volume":"114","author":"Isotani","year":"2006","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib21","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/bjp.2008.204","article-title":"Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders","volume":"154","author":"Jensen","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1939-1676.2005.tb02778.x","article-title":"A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats","volume":"19","author":"Lachowicz","year":"2005","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2009.05.007_bib23","first-page":"589","article-title":"Feline systemic mastocytosis: a review and results of splenectomy in seven cases","volume":"15","author":"Liska","year":"1979","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"10.1016\/j.vetimm.2009.05.007_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jfms.2005.12.005","article-title":"Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia","volume":"8","author":"Litster","year":"2006","journal-title":"J. Feline Med. Surg."},{"key":"10.1016\/j.vetimm.2009.05.007_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit","volume":"27","author":"London","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.vetimm.2009.05.007_bib27","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5326\/15473317-34-4-281","article-title":"Cutaneous mast cell tumours in cats: 32 cases (1991\u20131994)","volume":"34","author":"Molander-McCrary","year":"1998","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"10.1016\/j.vetimm.2009.05.007_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/002215540405200515","article-title":"C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections","volume":"52","author":"Morini","year":"2004","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.vetimm.2009.05.007_bib31","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.vetimm.2009.05.007_bib32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vetimm.2006.11.009","article-title":"Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells","volume":"115","author":"Rebuzzi","year":"2007","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib33","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/104063870501700416","article-title":"A study of mutations in the c-kit gene of 32 dogs with mastocytoma","volume":"17","author":"Riva","year":"2005","journal-title":"J. Vet. Diagn. Invest."},{"key":"10.1016\/j.vetimm.2009.05.007_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816 V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2009.05.007_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-5699(94)90153-8","article-title":"The riddle of the mast cell: kit(CD117)-ligand as the missing link?","volume":"15","author":"Valent","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/j.vetimm.2009.05.007_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.vetimm.2009.05.007_bib38","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood.V73.7.1778.1778","article-title":"Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes","volume":"73","author":"Valent","year":"1989","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.vetimm.2009.05.007_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.0960-135X.2004.01369.x","article-title":"On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts","volume":"34","author":"Valent","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.vetimm.2009.05.007_bib40","first-page":"399","article-title":"Systemic mastocytosis","volume":"142","author":"Valent","year":"2008","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.vetimm.2009.05.007_bib41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1439-0264.2002.00398.x","article-title":"Morphological and biochemical aspects of apoptosis, oncosis and necrosis","volume":"31","author":"Van Cruchten","year":"2002","journal-title":"Anat. Histol. Embryol."},{"key":"10.1016\/j.vetimm.2009.05.007_bib42","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vetimm.2009.05.007_bib43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1354\/vp.39-5-529","article-title":"Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs","volume":"39","author":"Zemke","year":"2002","journal-title":"Vet. Pathol."}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242709001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242709001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T05:35:21Z","timestamp":1589780121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242709001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":43,"journal-issue":{"issue":"2-4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0165242709001676"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2009.05.007","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}